vs
Side-by-side financial comparison of Cycurion, Inc. (CYCU) and Sensus Healthcare, Inc. (SRTS). Click either name above to swap in a different company.
Sensus Healthcare, Inc. is the larger business by last-quarter revenue ($4.9M vs $3.5M, roughly 1.4× Cycurion, Inc.). Sensus Healthcare, Inc. runs the higher net margin — -64.1% vs -141.2%, a 77.1% gap on every dollar of revenue. On growth, Cycurion, Inc. posted the faster year-over-year revenue change (-13.1% vs -62.2%). Sensus Healthcare, Inc. produced more free cash flow last quarter ($-2.4M vs $-3.5M). Over the past eight quarters, Cycurion, Inc.'s revenue compounded faster (-8.6% CAGR vs -31.9%).
Sensus Healthcare, Inc. is a medical technology company that designs, manufactures and commercializes innovative non-invasive superficial radiation therapy systems. Its products are primarily used for treating non-melanoma skin cancers, keloids, and select cosmetic dermatology conditions, serving healthcare providers and clinical facilities worldwide.
CYCU vs SRTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.5M | $4.9M |
| Net Profit | $-5.0M | $-3.2M |
| Gross Margin | 12.1% | 38.4% |
| Operating Margin | -141.7% | -63.8% |
| Net Margin | -141.2% | -64.1% |
| Revenue YoY | -13.1% | -62.2% |
| Net Profit YoY | -546.8% | -304.9% |
| EPS (diluted) | $-11.09 | $-0.19 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.5M | $4.9M | ||
| Q3 25 | $3.8M | $6.9M | ||
| Q2 25 | $3.9M | $7.3M | ||
| Q1 25 | $3.9M | $8.3M | ||
| Q4 24 | $4.1M | $13.1M | ||
| Q3 24 | $4.5M | $8.8M | ||
| Q2 24 | $5.0M | $9.2M | ||
| Q1 24 | $4.2M | $10.7M |
| Q4 25 | $-5.0M | $-3.2M | ||
| Q3 25 | $-3.1M | $-943.0K | ||
| Q2 25 | $-5.3M | $-1.0M | ||
| Q1 25 | $-10.2M | $-2.6M | ||
| Q4 24 | $1.1M | $1.5M | ||
| Q3 24 | $116.1K | $1.2M | ||
| Q2 24 | $306.1K | $1.6M | ||
| Q1 24 | $-312.5K | $2.3M |
| Q4 25 | 12.1% | 38.4% | ||
| Q3 25 | 7.1% | 39.4% | ||
| Q2 25 | 6.1% | 39.7% | ||
| Q1 25 | 17.5% | 52.2% | ||
| Q4 24 | 37.9% | 54.4% | ||
| Q3 24 | 16.1% | 59.3% | ||
| Q2 24 | 20.5% | 58.7% | ||
| Q1 24 | 8.2% | 62.5% |
| Q4 25 | -141.7% | -63.8% | ||
| Q3 25 | -118.2% | -37.3% | ||
| Q2 25 | -96.9% | -26.6% | ||
| Q1 25 | -260.9% | -31.7% | ||
| Q4 24 | 31.9% | 13.2% | ||
| Q3 24 | 9.4% | 16.9% | ||
| Q2 24 | 14.6% | 21.5% | ||
| Q1 24 | -0.8% | 27.1% |
| Q4 25 | -141.2% | -64.1% | ||
| Q3 25 | -81.5% | -13.7% | ||
| Q2 25 | -136.1% | -14.2% | ||
| Q1 25 | -264.8% | -30.8% | ||
| Q4 24 | 27.5% | 11.8% | ||
| Q3 24 | 2.6% | 13.7% | ||
| Q2 24 | 6.1% | 17.4% | ||
| Q1 24 | -7.4% | 21.3% |
| Q4 25 | $-11.09 | $-0.19 | ||
| Q3 25 | $-1.59 | $-0.06 | ||
| Q2 25 | $-0.15 | $-0.06 | ||
| Q1 25 | $-0.56 | $-0.16 | ||
| Q4 24 | $1.56 | $0.10 | ||
| Q3 24 | $0.11 | $0.07 | ||
| Q2 24 | $0.01 | $0.10 | ||
| Q1 24 | $-0.02 | $0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.3M | $22.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $20.1M | $48.1M |
| Total Assets | $33.5M | $53.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.3M | $22.1M | ||
| Q3 25 | $3.7M | $24.5M | ||
| Q2 25 | $1.0M | $22.2M | ||
| Q1 25 | — | $19.1M | ||
| Q4 24 | $38.7K | $22.1M | ||
| Q3 24 | — | $22.6M | ||
| Q2 24 | — | $19.0M | ||
| Q1 24 | — | $14.7M |
| Q4 25 | $20.1M | $48.1M | ||
| Q3 25 | $19.1M | $51.2M | ||
| Q2 25 | $14.0M | $52.1M | ||
| Q1 25 | $12.9M | $53.0M | ||
| Q4 24 | $3.5M | $55.8M | ||
| Q3 24 | $-3.7M | $54.1M | ||
| Q2 24 | $-3.4M | $52.9M | ||
| Q1 24 | $-2.8M | $51.2M |
| Q4 25 | $33.5M | $53.0M | ||
| Q3 25 | $32.3M | $58.3M | ||
| Q2 25 | $30.7M | $58.9M | ||
| Q1 25 | $31.5M | $60.2M | ||
| Q4 24 | $25.6M | $62.2M | ||
| Q3 24 | $2.9M | $59.9M | ||
| Q2 24 | $2.7M | $58.2M | ||
| Q1 24 | $3.1M | $57.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-3.3M | $-2.2M |
| Free Cash FlowOCF − Capex | $-3.5M | $-2.4M |
| FCF MarginFCF / Revenue | -98.8% | -47.9% |
| Capex IntensityCapex / Revenue | 5.3% | 3.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-12.5M | $332.0K |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-3.3M | $-2.2M | ||
| Q3 25 | $-2.5M | $2.3M | ||
| Q2 25 | $-3.6M | $3.1M | ||
| Q1 25 | $-2.7M | $-2.7M | ||
| Q4 24 | $-205.7K | $-827.0K | ||
| Q3 24 | $-315.2K | $4.0M | ||
| Q2 24 | $-578.0K | $4.2M | ||
| Q1 24 | $-272.4K | $-8.2M |
| Q4 25 | $-3.5M | $-2.4M | ||
| Q3 25 | $-2.6M | $2.3M | ||
| Q2 25 | $-3.7M | $3.1M | ||
| Q1 25 | $-2.8M | $-2.7M | ||
| Q4 24 | $-310.7K | $-1.1M | ||
| Q3 24 | $-420.2K | $3.6M | ||
| Q2 24 | $-711.0K | $4.2M | ||
| Q1 24 | $-377.4K | $-8.4M |
| Q4 25 | -98.8% | -47.9% | ||
| Q3 25 | -66.9% | 33.3% | ||
| Q2 25 | -94.2% | 42.2% | ||
| Q1 25 | -72.7% | -32.2% | ||
| Q4 24 | -7.6% | -8.6% | ||
| Q3 24 | -9.4% | 40.9% | ||
| Q2 24 | -14.2% | 45.8% | ||
| Q1 24 | -8.9% | -79.0% |
| Q4 25 | 5.3% | 3.2% | ||
| Q3 25 | 2.5% | 0.1% | ||
| Q2 25 | 2.7% | 0.4% | ||
| Q1 25 | 1.8% | 0.1% | ||
| Q4 24 | 2.6% | 2.3% | ||
| Q3 24 | 2.4% | 3.8% | ||
| Q2 24 | 2.7% | 0.0% | ||
| Q1 24 | 2.5% | 2.2% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -0.18× | -0.53× | ||
| Q3 24 | -2.71× | 3.25× | ||
| Q2 24 | -1.89× | 2.62× | ||
| Q1 24 | — | -3.60× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CYCU
Segment breakdown not available.
SRTS
| Products | $2.8M | 57% |
| Other | $2.1M | 43% |
